Detailed explanation of the medical insurance reimbursement policy for avatrombopag/Sucoxin

Avatrombopag/Suxin (Avatrombopag) is a new type of thrombopoietic drug, mainly used to treat thrombocytopenia related to chronic liver disease and immune thrombocytopenia (ITP). This drug works by stimulating the proliferation of megakaryocytes in the bone marrow, thereby promoting platelet production, and is indicated for adult patients who require diagnostic procedures or surgery. Due to its unique mechanism of action, avatrombopag has shown good clinical effects in increasing platelet counts and reducing the risk of bleeding.

In China, avatrombopag, as the original drug, received marketing authorization in 2020 and quickly entered the scope of national medical insurance Category B. However, its reimbursement policy is limited and only applies to eligible patients. Specifically, adults must be diagnosed with chronic liver disease and thrombocytopenia and require elective diagnostic procedures or surgery. This policy aims to ensure the rational allocation of medical insurance resources and give priority to patients in urgent need of medical assistance.

Common specifications of the drug include 15 tablets of 20mg and 10 tablets of 20mg, with prices roughly around RMB 7,000. This price may be prohibitive for many patients, so even though the drug is reimbursed by Medicare, affordability remains a challenge for patients. Before using Su Kexin, patients need to fully communicate with their doctors and make reasonable choices based on their health conditions and treatment needs.

The specific process of medical insurance reimbursement usually involves patients submitting relevant medical records, examination reports, doctor's prescriptions, etc. After review by the hospital, they then apply for reimbursement to the medical insurance department. This process may differ between different regions and hospitals. Patients should understand the local medical insurance policies and operating procedures in advance so that reimbursement can be completed smoothly.

Reference materials:https://go.drugbank.com/drugs/DB11995